CRDF · Cardiff Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | - | $120.0K | $121.0K | $109.0K | - | $165.0K | $163.0K | $205.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.76M | - | $8.20M | $11.58M | $10.48M | - | $9.64M | $9.49M | $8.01M | - |
| SG&A | $6.13M | - | $3.90M | $3.32M | $4.01M | - | $3.13M | $3.21M | $3.13M | - |
| Total Operating Expenses | $12.89M | - | $12.09M | $14.90M | $14.49M | - | $12.77M | $12.71M | $11.14M | - |
| D&A | $87.0K | - | $89.0K | $94.0K | $93.0K | - | - | - | $102.0K | - |
| Operating Income | ($12.85M) | - | ($11.97M) | ($14.78M) | ($14.38M) | - | ($12.60M) | ($12.54M) | ($10.93M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($12.35M) | - | ($11.26M) | ($13.94M) | ($13.43M) | - | ($11.86M) | ($11.78M) | ($10.01M) | - |
| EPS - Basic | ($0.18) | - | ($0.17) | ($0.21) | ($0.20) | - | ($0.25) | ($0.26) | ($0.22) | - |
| EPS - Diluted | ($0.18) | - | ($0.17) | ($0.21) | ($0.20) | - | ($0.25) | ($0.26) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.54M | $17.47M | $10.13M | $10.78M | $24.09M | $51.47M | $13.04M | $25.50M | $18.66M | $21.66M |
| Accounts Receivable | $191.0K | $182.0K | $254.0K | $526.0K | $405.0K | $773.0K | $618.0K | $451.0K | $393.0K | $288.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.48M | $8.09M | $2.44M | $6.01M | $3.63M | $4.82M | $4.64M | $5.11M | $5.19M | $1.97M |
| Current Assets | $47.34M | $60.13M | $61.80M | $73.70M | $82.71M | $95.05M | $59.33M | $62.25M | $69.99M | $77.41M |
| Total Assets | $49.17M | $61.88M | $63.78M | $75.74M | $84.81M | $97.19M | $62.90M | $66.05M | $74.04M | $81.64M |
| Current Liabilities | $14.46M | $16.39M | $14.71M | $16.67M | $13.29M | $13.43M | $12.53M | $12.52M | $11.84M | $10.44M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.46M | $16.50M | $14.99M | $17.13M | $13.93M | $14.24M | $13.50M | $13.66M | $13.14M | $11.90M |
| Stockholders' Equity | $34.71M | $45.39M | $48.79M | $58.61M | $70.88M | $82.95M | $49.39M | $52.39M | $60.89M | $69.74M |
| Retained Earnings | ($442.38M) | ($430.03M) | ($422.81M) | ($411.56M) | ($397.61M) | ($384.18M) | ($372.39M) | ($360.54M) | ($348.76M) | ($339.54M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.29M) | - | - | - | ($12.79M) | - | - | - | ($7.74M) | - |
| Investing Cash Flow | $3.26M | - | - | - | ($14.58M) | - | - | - | $4.64M | - |
| Financing Cash Flow | $105.0K | - | - | - | $3.0K | - | - | - | $107.0K | - |
| CapEx | - | - | - | - | - | - | - | - | $80.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($7.82M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -31341.5% | - | -9978.3% | -12212.4% | -13194.5% | - | -7637.0% | -7696.3% | -5333.2% | - |
| EBITDA margin | -31129.3% | - | -9904.2% | -12134.7% | -13109.2% | - | - | - | -5283.4% | - |
| Net margin | -30109.8% | - | -9381.7% | -11523.1% | -12324.8% | - | -7184.8% | -7225.8% | -4883.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -3814.6% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.78 | - |
| R&D / Revenue | 16500.0% | - | 6830.8% | 9570.2% | 9611.9% | - | 5842.4% | 5823.9% | 3906.3% | - |
| SG&A / Revenue | 14941.5% | - | 3247.5% | 2742.1% | 3682.6% | - | 1894.5% | 1972.4% | 1526.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.1% | - | -17.7% | -18.4% | -15.8% | - | -18.8% | -17.8% | -13.5% | - |
| Return on equity | -35.6% | - | -23.1% | -23.8% | -19.0% | - | -24.0% | -22.5% | -16.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.27 | 3.67 | 4.20 | 4.42 | 6.22 | 7.08 | 4.74 | 4.97 | 5.91 | 7.41 |
| Quick ratio | 3.27 | 3.67 | 4.20 | 4.42 | 6.22 | 7.08 | 4.74 | 4.97 | 5.91 | 7.41 |
| Cash ratio | 0.59 | 1.07 | 0.69 | 0.65 | 1.81 | 3.83 | 1.04 | 2.04 | 1.58 | 2.07 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.42 | 1.36 | 1.31 | 1.29 | 1.20 | 1.17 | 1.27 | 1.26 | 1.22 | 1.17 |
| Liabilities / Assets | 0.29 | 0.27 | 0.24 | 0.23 | 0.16 | 0.15 | 0.21 | 0.21 | 0.18 | 0.15 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 1700d | - | 773d | 1587d | 1356d | - | 1367d | 1010d | 700d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.2x | - | 2.8x | 3.6x | 2.9x | - | 2.5x | 1.9x | 3.9x | - |
| P / S | 2700.7x | - | 1148.1x | 1731.9x | 1916.4x | - | 758.4x | 610.5x | 1163.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -62.4% | - | -27.3% | -25.8% | -46.8% | - | 17.0% | 50.9% | 147.0% | - |
| Revenue CAGR (3y) | -20.9% | - | 8.9% | 10.0% | 13.8% | - | 24.3% | 33.8% | 41.7% | - |
| Revenue CAGR (5y) | -10.7% | - | -2.5% | 23.2% | 10.0% | - | 13.3% | 7.8% | 4.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 10.7% | - | 5.0% | -17.8% | -31.5% | - | -16.5% | -2.8% | 9.3% | - |
| Net income growth (YoY) | 8.1% | - | 5.0% | -18.4% | -34.2% | - | -21.8% | -5.6% | 10.8% | - |
| EPS growth (YoY) | 10.0% | - | 32.0% | 19.2% | 9.1% | - | -13.6% | -4.0% | 12.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 9.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -51.0% | -45.3% | -1.2% | 11.9% | 16.4% | 18.9% | -36.5% | -39.5% | -36.9% | -34.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$366.0K totalRoyalty$366.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cardiff Oncology against the 5 most active filers in the same SIC group.